Propanc Biopharma Files 8-K: Material Agreement & Equity Sales
Ticker: PPCB · Form: 8-K · Filed: Feb 12, 2025 · CIK: 1517681
| Field | Detail |
|---|---|
| Company | Propanc Biopharma, Inc. (PPCB) |
| Form Type | 8-K |
| Filed Date | Feb 12, 2025 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $65,000, $56,000, $65,000.00, $9,750.00, $37,375 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-sale
TL;DR
Propanc Biopharma inked a deal, took on debt, and sold stock on Feb 6th.
AI Summary
Propanc Biopharma, Inc. entered into a material definitive agreement on February 6, 2025. The company also created a direct financial obligation and reported unregistered sales of equity securities. The filing includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate activity, including new financial obligations and equity transactions, which could impact the company's financial structure and shareholder value.
Risk Assessment
Risk Level: medium — The filing details material definitive agreements, financial obligations, and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- Propanc Biopharma, Inc. (company) — Registrant
- February 6, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 000-54878 (file_number) — SEC File Number
FAQ
What type of material definitive agreement did Propanc Biopharma, Inc. enter into?
The filing states that Propanc Biopharma, Inc. entered into a 'Material Definitive Agreement' on February 6, 2025, but the specific details of the agreement are not provided in the provided text.
What is the nature of the direct financial obligation created by Propanc Biopharma, Inc.?
The filing indicates the creation of a 'Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant,' but the specific terms and amount of the obligation are not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 6, 2025.
What is Propanc Biopharma, Inc.'s state of incorporation and SEC file number?
Propanc Biopharma, Inc. is incorporated in Delaware and its SEC file number is 000-54878.
What are the main items reported in this Form 8-K?
This Form 8-K reports on the entry into a Material Definitive Agreement, the creation of a Direct Financial Obligation, unregistered sales of equity securities, and includes financial statements and exhibits.
Filing Stats: 1,596 words · 6 min read · ~5 pages · Grade level 12.2 · Accepted 2025-02-12 16:10:57
Key Financial Figures
- $65,000 — ny in the aggregate principal amount of $65,000 (the "Note"), for a purchase price of $
- $56,000 — 0 (the "Note"), for a purchase price of $56,000. The Company intends to use the net pro
- $65,000.00 — on the Issuance Date to the Principal ($65,000.00 * fifteen percent (15%) = $9,750.00). A
- $9,750.00 — l ($65,000.00 * fifteen percent (15%) = $9,750.00). Accrued, unpaid interest and outstand
- $37,375 — ts, with the first on July 30, 2025 for $37,375.00, and the other four payments of $9,3
- $9,343.75 — ,375.00, and the other four payments of $9,343.75 on August 30, 2025, September 30, 2025,
- $74,750.00 — 2025 (a total payback to the Holder of $74,750.00). The Company shall have a five (5) day
- $43,000 — ny in the aggregate principal amount of $43,000 (the "Note"), for a purchase price of $
- $40,000 — 0 (the "Note"), for a purchase price of $40,000. The Company intends to use the net pro
- $0.001 — common stock of the Company, par value $0.001 per share (the "Common Stock"), at the
- $9.00 — onversion Shares") at a price per share $9.00. per share, Provided, however, that in
- $8.00 — the Company's Common Stock trades below $8.00 per share for more than five (5) consec
- $6.00 — then the Fixed Price shall be equal to $6.00 per share. In the Event of Default, the
Filing Documents
- form8-k.htm (8-K) — 50KB
- ex4-1.htm (EX-4.1) — 94KB
- ex4-2.htm (EX-4.2) — 60KB
- ex10-1.htm (EX-10.1) — 75KB
- ex10-2.htm (EX-10.2) — 78KB
- 0001493152-25-006126.txt ( ) — 594KB
- ppcb-20250206.xsd (EX-101.SCH) — 3KB
- ppcb-20250206_lab.xml (EX-101.LAB) — 33KB
- ppcb-20250206_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 11, 2025 PROPANC BIOPHARMA, INC. By: /s/ James Nathanielsz Name: James Nathanielsz Title: Chief Executive Officer and Chief Financial Officer